Press coverage about Medidata Solutions (NASDAQ:MDSO) has been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Medidata Solutions earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.5635915688833 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Several research analysts recently weighed in on the stock. Morgan Stanley dropped their price objective on shares of Medidata Solutions from $86.00 to $79.00 and set an “overweight” rating for the company in a research report on Friday, February 9th. ValuEngine cut shares of Medidata Solutions from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st. Zacks Investment Research upgraded shares of Medidata Solutions from a “hold” rating to a “buy” rating and set a $70.00 price objective for the company in a research report on Wednesday, February 14th. Deutsche Bank assumed coverage on shares of Medidata Solutions in a research report on Friday, December 8th. They issued a “buy” rating and a $78.00 price objective for the company. Finally, BidaskClub upgraded shares of Medidata Solutions from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $82.07.
Shares of Medidata Solutions (NASDAQ MDSO) opened at $68.57 on Wednesday. The company has a current ratio of 1.49, a quick ratio of 1.49 and a debt-to-equity ratio of 0.19. Medidata Solutions has a fifty-two week low of $54.91 and a fifty-two week high of $85.92. The company has a market cap of $4,149.88, a price-to-earnings ratio of 92.66, a price-to-earnings-growth ratio of 3.54 and a beta of 1.56.
In other news, CFO Rouven Bergmann sold 3,000 shares of the business’s stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $70.00, for a total value of $210,000.00. Following the completion of the transaction, the chief financial officer now owns 84,775 shares of the company’s stock, valued at approximately $5,934,250. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Tarek Sherif sold 26,836 shares of the business’s stock in a transaction on Monday, March 12th. The shares were sold at an average price of $70.25, for a total transaction of $1,885,229.00. The disclosure for this sale can be found here. Insiders have sold a total of 35,836 shares of company stock valued at $2,494,989 in the last ninety days. Company insiders own 5.80% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.themarketsdaily.com/2018/03/14/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-medidata-solutions-mdso-share-price.html.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.